These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25192579)

  • 1. [Progress of anticoagulation therapy in atrial fibrillation].
    Hernández Olmedo M; Suárez Fernández C
    Med Clin (Barc); 2015 Aug; 145(3):124-30. PubMed ID: 25192579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anticoagulation for patients with non-valvular atrial fibrillation].
    Mizoguchi T; Yasaka M
    Nihon Rinsho; 2016 Apr; 74(4):627-33. PubMed ID: 27333751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Anticoagulants in Atrial Fibrillation: A Primer for the Primary Physician.
    Mookadam M; Shamoun FE; Mookadam F
    J Am Board Fam Med; 2015; 28(4):510-22. PubMed ID: 26152444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
    Seeger JD; Bykov K; Bartels DB; Huybrechts K; Zint K; Schneeweiss S
    Thromb Haemost; 2015 Nov; 114(6):1277-89. PubMed ID: 26446507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
    Aguilar MI; Kuo RS; Freeman WD
    Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Security profile of direct anticoagulants. Preferred use in atrial fibrillation.
    Roldán Rabadán I; Alonso de Leciñana M; Barba Martín R; Páramo Fernández JA;
    Clin Investig Arterioscler; 2019; 31(6):263-270. PubMed ID: 31213323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which drug should we use for stroke prevention in atrial fibrillation?
    Lau YC; Lip GY
    Curr Opin Cardiol; 2014 Jul; 29(4):293-300. PubMed ID: 25029448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
    Martínez-Rubio A; Dan GA; Kaski JC
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroke prevention in atrial fibrillation: do we still need warfarin?
    Diener HC; Weber R; Lip GY; Hohnloser SH
    Curr Opin Neurol; 2012 Feb; 25(1):27-35. PubMed ID: 22143201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.
    Buller HR; Halperin J; Hankey GJ; Pillion G; Prins MH; Raskob GE
    J Thromb Haemost; 2014 Jun; 12(6):824-30. PubMed ID: 24597472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation.
    Alberts MJ; Eikelboom JW; Hankey GJ
    Lancet Neurol; 2012 Dec; 11(12):1066-81. PubMed ID: 23153406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newer anticoagulants as an alternate to warfarin in atrial fibrillation: a changing paradigm.
    Chaudhari D; Bhuriya R; Arora R
    Am J Ther; 2011 Jan; 18(1):e1-e11. PubMed ID: 20460986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants.
    Hankey GJ
    Thromb Haemost; 2014 May; 111(5):808-16. PubMed ID: 24285341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC; Easton JD; Hankey GJ; Hart RG
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.